Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
<b>Background and Aim:</b> Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness a...
| Автори: | , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
MDPI AG
2025-02-01
|
| Серія: | Metabolites |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2218-1989/15/2/100 |